Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Neurocrine Biosciences history
Neurocrine Biosciences company history timeline
Neurocrine was founded in San Diego, California, in 1992.
The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.
In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds.
In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon.
In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations.
Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies.
In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan.
Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008.
In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome.
Rate how well Neurocrine Biosciences lives up to its initial vision.
Neurocrine Biosciences jobs
Do you work at Neurocrine Biosciences?
Is Neurocrine Biosciences' vision a big part of strategic planning?
Neurocrine Biosciences competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Regeneron | 1988 | $14.2B | 9,123 | 334 |
| Amgen | 1980 | $33.4B | 22,000 | 573 |
| Seagen | 1997 | $2.0B | 900 | - |
| Gilead Sciences | 1987 | $28.8B | 11,800 | 600 |
| Merck | 1891 | $64.2B | 74,000 | 1,544 |
| Sanofi Genzyme | 1981 | $4.6B | 12,000 | - |
| Human Genome Sciences | 1992 | $131.0M | 1,000 | - |
| Hospira | 2004 | $4.5B | 19,000 | - |
| Halozyme | 1998 | $1.0B | 136 | 17 |
| Aeras | 2003 | $39.3M | 72 | - |
Neurocrine Biosciences history FAQs
Zippia gives an in-depth look into the details of Neurocrine Biosciences, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Neurocrine Biosciences. The employee data is based on information from people who have self-reported their past or current employments at Neurocrine Biosciences. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Neurocrine Biosciences. The data presented on this page does not represent the view of Neurocrine Biosciences and its employees or that of Zippia.
Neurocrine Biosciences may also be known as or be related to NEUROCRINE BIOSCIENCES. INC, Neurocrine Biosciences, Neurocrine Biosciences Inc, Neurocrine Biosciences Inc. and Neurocrine Biosciences, Inc.